報價延遲最少15分鐘:2025/02/23 04:18 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.07 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-10.13/-0.12
|
|
企業價值
12.81M
|
| 資產負債 |
|
每股賬面淨值
2.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
5.18M
|
|
每股收益
2.40
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 04:18 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa. |